Close Menu

Breaking News

The activity of the ABE8e editor is increased 590-fold compared to the activity of the ABE7.10, and it can be paired with a variety of Cas9 or Cas12 homologs. 

The firms are developing clinical and RUO workflows that use NGS for pathogen identification and will comarket IDbyDNA's Explify data platform.

The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.

In a guidance, the agency described expanded policies that will enable manufacturers, local labs, and others to quickly deploy coronavirus testing. 

Hologic and LabCorp became the third and fourth commercial test makers to receive EUA designation for  assays to detect the coronavirus that causes COVID-19.

The analysis of a hippocampus cell layer uncovered genetic loci associated with schizophrenia risk, including two that may represent drug targets.

The effort is focused on building an atlas of immune cell types found across a range of Asian population groups as part of the Human Cell Atlas project.

The company will not be allowed to submit another plan for meeting the Nasdaq's listing requirements.

Last week, GenomeWeb's readers were most interested in the pain points labs are encountering in their coronavirus assay validations.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.

The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.

As part of the placement, the Singapore-based firm has issued almost 17.9 million new ordinary shares at an issue price of $.175 per share. 

A pathologists' group has pointed out that the bill covers only EUA tests, and patients receiving tests with pending regulatory status may receive surprise bills.

In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity

The test, authorized March 13, runs on the Applied Biosystems 7500 Fast Dx Real-Time PCR instrument and targets three regions of the SARS-CoV-2 genome.

According to the recall, initiated on Jan. 28, a glitch in the software’s data reporting to LIM systems could cause false-negative results from PCR assays running on the instrument.

The funds will support development of an assay on the DiaSorin Liason MDX sample-to-answer instrument.

Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology. 

PreCheck Health has an initial order of 30,000 tests and will register the product in Ecuador. The two firms have a similar distribution agreement covering Russia.

The agency will reimburse at about $35.91 per test for CDC assays and about $51.31 per test for non-CDC assays.

News items for the week of March 9, 2020.

BioReference is also now accepting specimens for testing SARS-CoV-2 and expects to offer 5,000 tests a day at satellite testing sites next week.

Under the NYSDOH's approach, labs need to provide validation data within 15 days of starting to test instead of having to pursue an EUA with the FDA.

The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.

Pages

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.